A first of its kind “self-blinded” trial testing the effect of psychedelic microdosing has found the anecdotally popular practice may be an example of a strong placebo effect.

The Mental Health Crisis is a huge opportunity for psychedelic drugs. But the BIGGEST potential markets may exist outside of mental health.

The completed equity investment strengthens ties between MINDCURE and ATMA

MINDCURE makes a CAD$500,000 strategic investment in ATMA Journey Centers, an Alberta-based psychedelics-assisted mental health clinic.

Field Trip Health just announced the 3rd largest financing by a psychedelics public company: a CAD$82.875 million bought deal. Here’s what it means for investors.

New York University wants to expand our minds — but in a trippy new way.

Psychedelic therapy has been gaining not only popularity but acceptance in the medical community in recent years.

Optimi Health has commenced public trading (symbol “OPTI”). The Company raised CAD$20.7 million for its IPO financing.

With its (upsized) $82.875 million dollar financing, Field Trip establishes itself as one of the industry leaders in the psychedelics space.

Although one may think of psychedelic pharmaceuticals as being dangerous and detrimental, scientists have been conducting experiments and clinical trials on some of them and have obtained positive results when testing them for medical use.